Loading organizations...

§ Venture Capital · Tel Aviv, Israel
Early-stage venture capital firm investing in technology and healthcare startups, offers capital and strategic support to scale internationally.
INKEF Capital is an early-stage venture capital firm that invests in technology and healthcare startups, headquartered in Amsterdam, Netherlands. The firm provides long-term capital and hands-on strategic support to help entrepreneurs scale their ventures internationally, focusing on sectors such as ICT, New Media, FinTech, software, pharma, and medtech. INKEF has raised a total fund of €500 million, with €300 million committed by 2017, and maintains sufficient capital for portfolio follow-ons through at least 2028. Managing Directors Robert Jan Galema and Roel Bulthuis oversee the firm's operations, alongside former Partner Kyang Yung. While founding partner ABP, a Dutch pension fund, discontinued new investments in 2023 to focus on climate initiatives, existing commitments remain secure for the fund. INKEF Capital was founded in 2010 by ABP.
Key people at INKEF Capital.
Key people at INKEF Capital.
INKEF Capital is a European venture capital firm headquartered in Amsterdam, specializing in early-stage investments primarily in technology and healthcare sectors. The firm adopts a patient, long-term investment philosophy, focusing on supporting startups through multiple funding rounds with strategic guidance and operational support to foster successful international growth. Its key sectors include healthcare technologies (biotechnology, medical devices, digital health), SaaS, AI, fintech, and industrial tech. INKEF’s impact on the startup ecosystem lies in its active role in scaling innovative companies with disruptive and scalable business models, leveraging a strong network of industry experts to accelerate growth and market leadership across Europe and the US[1][2][5].
Founded in 2010, INKEF Capital was established with backing from the Dutch pension fund ABP, which provides a solid financial foundation. The firm’s founding partners and leadership have evolved its focus to blend deep expertise in both healthcare and technology, enabling it to invest effectively at the intersection of these fields. Early on, INKEF distinguished itself by committing to a patient capital approach, emphasizing long-term collaboration rather than quick exits. This approach has helped portfolio companies like Cashforce (fintech) and Calypso Biotech (immunology) achieve significant growth and international expansion[1][2].
INKEF Capital rides the wave of digital transformation in healthcare and technology, particularly at the convergence of life sciences and software innovation. The timing is critical as healthcare undergoes rapid shifts toward decentralized, personalized, and value-based models, creating fertile ground for tech-enabled health solutions. Market forces such as increasing healthcare digitization, AI adoption, and demand for scalable tech solutions favor INKEF’s investment thesis. By backing early-stage companies with disruptive technologies, INKEF influences the broader ecosystem by accelerating innovation, fostering cross-border growth, and helping European startups compete globally[2][3].
Looking ahead, INKEF Capital is poised to deepen its impact by continuing to invest in cutting-edge healthcare and technology startups that address emerging global challenges. Trends such as AI in healthcare, personalized medicine, and industrial tech innovation will likely shape its portfolio. The firm’s patient, long-term approach positions it well to support companies through complex scaling phases and evolving market dynamics. As healthcare and technology sectors increasingly intertwine, INKEF’s influence as a strategic partner and capital provider is expected to grow, reinforcing its role as a key driver of European innovation and international expansion[3][5].
INKEF Capital has more than 26 tracked investments across 25 companies. The latest tracked deal is $40.0M Series B in Silverflow in March 2026.